clinical trial · NCT04455841
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
AnemiaPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera MyelofibrosisINCB000928ruxolitinib
brief summary
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.
started
Mar 19, 2021
primary completion
Apr 1, 2025
completion
Nov 26, 2027
last updated
May 14, 2026
official title
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol